This Site makes heavy use of JavaScript

Either you have JavaScript disabled or your browser does not support JavaScript.

To work properly, this page requires JavaScript to be enabled. If you can enable it in your browser's preferences, you may have a better experience.

Mechanism of Action | Pradaxa® (dabigatran etexilate) Skip to main content

VKA=vitamin K antagonist; NOAC=novel oral anticoagulant

  • References:
  • 1. Data on File. Boehringer Ingelheim Pharmaceuticals, Inc.
  • 2. Pradaxa [prescribing information]. Ridgefield, CT: Boehringer Ingelheim Pharmaceuticals, Inc.
  • 3. Lassen MR, Laux V. Emergence of new oral antithrombotics: a critical appraisal of their clinical potential. Vasc Health Risk Manag. 2008;4(6):1373‑1386.
  • 4. Ansell J. Factor Xa or thrombin: is factor Xa a better target? J Thromb Haemost. 2007;5(suppl 1):60‑64.
  • 5. Coumadin [prescribing information]. Princeton, NJ: Bristol‑Myers Squibb Company; October 2011.
  • 6. Xarelto [prescribing information]. Titusville, NJ: Janssen Pharmaceuticals, Inc.; March 2013.
  • 7. Eliquis [prescribing information]. Princeton, NJ: Bristol‑Myers Squibb Company; August 2014.